Crispr Therapeutics Stock News

Despite big gains today, the biotech specialist''s share price is still down roughly 46% over the past year of trading.

Recent comments from the company's CEO are prompting bullish momentum for the stock.

Despite big gains today, the biotech specialist's share price is still down roughly 46% over the past year of trading.

CRISPR Therapeutics' (CRSP) CEO Sam Kulkarni on Cowen 42nd Annual Health Care Conference (Transcript)

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.19, moving -1.85% from the previous trading session.

Sometimes yes, but the risks are similar in magnitude too.

CRISPR Therapeutics' share price has fallen by half across the past 12 months - although the company is making solid progress and may soon win approval in Sickle Cell Disease.

Keep your eyes on the prize.

The decision is a setback for Intellia Therapeutics, Crispr Therapeutics, and Caribou Biosciences, and a win for Editas Medicine and Beam Therapeutics.

Buffett's latest letter to Berkshire Hathaway shareholders revealed the legendary investor's present mindset.

Savvy investors can generate lucrative returns by investing in companies that look like prime takeover targets. This article speculates on a number of takeover targets of 2022.

On CNBCs "Mad Money Lightning Round," Jim Cramer said CRISPR Therapeutics AG (NASDAQ: CRSP ) is likely to "lose a lot of money. But more importantly, this is the kind of company right now that is so out of favor that, unless you are willing to take a beating, which I do not encourage, I think you have to take a pass on it," With American Airlines Group Full story available on Benzinga.com

CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Their long-term prospects appear to be bright.